Drugmaker Pulls Impotence Drug out of FDA Approval Process
June 30, 2000 (Washington) -- Of the 30 million American men suffering from erectile dysfunction, those expecting to have an alternative to Viagra soon will now have to wait. The approval application for the erectile dysfunction drug Uprima (apomorphine) was withdrawn by its maker Friday -- just days before the FDA was to render a final decision and despite data demonstrating it might prove to be a safer alternative for patients with heart disease.
Apomorphine has been used to treat various disorders since 1869. For the last half of the 20th century, it has been used as a sedative, and since 1967 as a treatment for Parkinson's disease. In men suffering from erectile dysfunction, the drug stimulates brain centers involved in sexual response and activates spinal nerves to increase blood flow to erectile tissue.
TAP Pharmaceuticals, a joint venture between Abbott Laboratories of Abbott Park, Ill., and Japan's Takeda Chemical Industries, said it decided to withdraw the application for Uprima so it can complete several ongoing studies to confirm the drug's safety and effectiveness. The FDA nod initially was expected in July based on advice from a FDA expert advisory committee, which in April voted 9-3 to recommend that agency officials proceed with its approval.
The FDA committee supported approval of Uprima despite the potential for serious side effects when it is taken with nitrates, a common drug for heart disease, and its apparent interaction with alcohol, which could lead to dangerously low blood pressure, a slow heart rate, and fainting. Viagra also can cause adverse reactions when taken with nitrates. The committee also voted for approval despite questions regarding the overall effectiveness of Uprima. These questions center on whether the clinical trials of the drug truly included men with severe sexual dysfunction.
In those clinical trials, more than half of the treatment group achieved an erection compared with 35% of those patients on placebo. The relatively high rate of responders in the placebo group suggests that the patients included in the studies may not have suffered from severe sexual dysfunction, a number of committee members noted.